Chapter
Increased in Small, Dense LDL Particles
DYSLIPIDEMIA AND CV OUTCOME IN CKD
Lp(a) Concentrations and Apo(a) Polymorphism
Effect of Statins in Primary Prevention of CVD in ESRD Patients
Non-Statins Lipid Lowering Agents
Chapter 4 CHRONIC KIDNEY DISEASE – MINERAL BONE DISEASE (CKD-MBD): PRESENT AND FUTURE PERSPECTIVES
CALCIUM, PHOSPHATE, PTH AND VITAMIN D HOMEOSTASIS IN NORMAL RENAL FUNCTION CONDITION
BONE MINERAL ABNORMALITIES IN CHRONIC KIDNEY DISEASE: THE PHOSPHOROCENTRIC PARADIGM
CLINICAL CONSEQUENCES OF CKD-MBD
TREATMENT STRATEGIES IN CKD-MBD
UNMET MEDICAL NEED AND FUTURE PERSPECTIVES
Chapter 5 ANEMIA MANAGEMENT IN PATIENTS WITH CHRONIC KIDNEY DISEASE
DIAGNOSIS AND EVALUATION OF ANEMIA IN CKD
USE OF IRON TO TREAT ANEMIA IN CKD
USE OF ERYTHROPOIETIC-STIMULATING AGENTS TO TREAT ANEMIA IN CKD
RED CELL TRANSFUSION TO TREAT ANEMIA IN CKD
Chapter 6 CORONARY ARTERY DISEASE AND CHRONIC KIDNEY DISEASE
CORONARY REVASCULARIZATION
Chapter 7 ARRHYTHMIAS AND SUDDEN CARDIAC DEATH IN CHRONIC KIDNEY DISEASE
Incidence of Cardiac Sudden Death in General Population
Incidence of SCD in CKD Patients
RISK FACTORS AND HYPOTHESIZED MECHANISMS OF SCD IN CKD
THERAPEUTIC STRATEGIES TO PREVENT SCD
Non-Pharmacological Options
Chapter 8 CARDIORENAL SYNDROME
1. TYPE – 1 CARDIO – RENAL SYNDROME
1.3. Outcomes and Treatment
2. TYPE – 2 CARDIO – RENAL SYNDROME
2.3. Outcomes and Treatment
3. TYPE – 3 CARDIORENAL SYNDROME
3.3. Outcomes and Treatment
4. TYPE – 4 CARDIO RENAL SYNDROME
4.3. Outcomes and Treatment
5. TYPE – 5 CARDIO RENAL SYNDROME
5.3. Outcomes and Treatment
Chapter 9 THE HEPATO – RENAL SYNDROME
HEPATO – RENAL SYNDROME: DEFINITION
PATHOGENESIS OF HEPATO – RENAL SYNDROME
DIAGNOSIS AND BIOMARKERS OF HRS
a) Pharmacological Approach
b) Non – Pharmacological Approach
Chapter 10 CONTRAST-INDUCED ACUTE KIDNEY INJURY